Victory Capital Management Inc. Reduces Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Victory Capital Management Inc. cut its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 13.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,893,193 shares of the medical equipment provider's stock after selling 764,824 shares during the period. Victory Capital Management Inc. owned about 2.11% of Hologic worth $398,600,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Innealta Capital LLC purchased a new position in Hologic during the second quarter valued at $25,000. Wolff Wiese Magana LLC purchased a new position in shares of Hologic in the 3rd quarter worth $25,000. iA Global Asset Management Inc. purchased a new position in shares of Hologic in the 1st quarter worth $37,000. Sunbelt Securities Inc. purchased a new position in shares of Hologic in the 2nd quarter worth $37,000. Finally, Cromwell Holdings LLC grew its stake in shares of Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after buying an additional 416 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

NASDAQ:HOLX traded up $0.37 during trading hours on Tuesday, reaching $79.76. 1,974,743 shares of the company were exchanged, compared to its average volume of 1,593,289. Hologic, Inc. has a twelve month low of $67.59 and a twelve month high of $84.67. The firm has a market cap of $18.53 billion, a PE ratio of 23.84, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. The stock's 50-day moving average is $80.93 and its 200-day moving average is $78.19. The company has a current ratio of 3.69, a quick ratio of 3.32 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the firm earned $0.89 earnings per share. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HOLX. Stephens restated an "overweight" rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Raymond James raised their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Evercore ISI lifted their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a report on Tuesday, October 1st. Finally, Needham & Company LLC reiterated a "buy" rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $89.25.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.